Expression of sex steroid receptors and IGF-1 mRNA in breast tissue - Effects of hormonal treatment

Journal of Steroid Biochemistry and Molecular Biology

Volumn 70, Issue 4-6, 1999, Pages 257-262

  Isaksson, Erika ^a   Sahlin, Lena ^b   Söderqvist, Gunnar ^c   Von Schoultz, Eva ^a   Masironi, Britt ^b   Wickman, Marie ^c   Wilking, Nils ^a   Von Schoultz, Bo ^c   Skoog, Lambert ^c  

^a Karolinska Institutet   (Sweden)

^b Department of Woman and Child Health   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ESTRADIOL; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; LEVONORGESTREL; NORETHISTERONE; PROGESTERONE RECEPTOR; SOMATOMEDIN C; STEROID RECEPTOR;

ADULT; ARTICLE; BREAST; BREAST REDUCTION; CANCER RISK; FEMALE; GENE EXPRESSION; HORMONAL CONTRACEPTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; TISSUE GROWTH;

EID: 0032705527     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(99)00115-6     Document Type: Article

References (34)

1. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 347:1996;1713-1727.
2. Olsson H., Möller T.R., Ranstam J. Early oral contraceptive use and premenopausal breast cancer - final report from a study in southern Sweden. J. Natl. Cancer Inst. 81:1989;1000-1004.
3. Colditz G.A., Egan K.M., Stampfer M.J. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am. J. Obstet. Gynecol. 168:1993;1473-1480.
4. Grady D., Rubin S.M., Petitti D.B., Fox C.S., Black D., Ettinger B., Ernster V.L., Cummings S.R. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117:1992;1016-1037.
5. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15:1993;17-35.
6. Spicer D.V., Pike M.C. Sex steroids and breast cancer prevention. J. Natl. Cancer Inst. Monogr. 16:1994;139-147.
7. Williams G., Anderson E., Howell A., Watson R., Coyne J., Roberts S.A., Potten C.S. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int. J. Cancer. 48:1991;206-210.
8. Battersby S., Robertson B.J., Anderson T.J., King R.J.B., McPherson K. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br. J. Cancer. 65:1992;601-607.
9. Cline J.M., Söderqvist G., von Schoultz B., Skoog L., von Schoultz E. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal macaques. Am. J. Obstet. Gynecol. 174:1996;93-100.
10. Moore M.R., Hathaway L.D., Bircher J.A. Progestin stimulation of thymidine kinase in the human breast cancer cell line T47D. Biochim. Biophys. Acta. 1096:1991;1174-1180.
11. Goldfine I.D., Papa V., Vignieri R., Süteri P., Rosenthal S. Progestin regulation of insulin and insulin-like growth factor 1 receptors in cultured human breast cancer cells. Breast Cancer Res. Treat. 22:1992;69-79.
12. Takatani O., Kosano H., Okumoto T., Akamatsu K., Tamakuma S., Hiraide H. Distribution of estradiol and percentage of free testosterone in sera of Japanese women: Preoperative breast cancer and normal controls. J. Natl. Cancer Inst. 79:1987;1199-1204.
13. Winston R., Kao P.C., Kiang D.T. Regulation of insulin-like growth factors by antiestrogen. Breast Cancer Res. Treat. 31:1994;107-115.
14. Reid S.E., Murthy M.S., Kaufman M., Scanlon E.F. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br. J. Surg. 83:1996;1037-1046.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
16. Sahlin L., Norstedt G., Eriksson H. Estrogen regulation of the estrogen receptor and insulin-like growth factor-1 in the rat uterus; a potential coupling between effects of estrogen and IGF-1. Steroids. 59:1994;421-430.
17. Cattoretti G., Becker M.H., Key G., Duchrow M., Schluter C., Calle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 168:1992;357-363.
18. Gerdes J., Li L., Schlueter C., Duchrow M., Wohlenberg C., Gerlach C., Stahmer I., Kloth S., Brandt E., Flad H.D. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol. 138:1991;867-873.
19. Anderson T.J., Battersby S., King R.J., McPherson K., Going J.J. Oral contraceptive use influences resting breast proliferation. Human Pathol. 20:1989;1139-1144.
20. Potten C.S., Watson R.J., Williams G.T., Tickle S., Robert S.A., Harris M., Howell A. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br. J. Cancer. 58:1988;163-170.
21. Söderqvist G., Isaksson E., von Schoultz B., Carlström K., Tani E., Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am. J. Obstet. Gynecol. 176:1997;123-128.
22. Stjernholm Y., Sahlin L., Åkerberg S., Elinder A., Eriksson H.A., Malmström A., Ekman G. Cervical ripening in humans: potential roles of estrogen, progesterone, and insulin-like growth factor-1. Am. J. Obstet. Gynecol. 174:1996;1065-1071.
23. Söderqvist G., von Schoultz B., Tani E., Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am. J. Obstet. Gynecol. 168:1993;874-879.
24. Peterson O.W., Hoyer P.E., van Deurs B. Frequency and distribution of oestrogen receptor-positive cells in normal nonlactating human breast tissue. Cancer Res. 47:1987;5748-5751.
25. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393-1396.
26. Lee A.V., Weng C-N., Jackson J.G., Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J. Endocrinol. 152:1997;39-47.
27. Kazer R.R. Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int. J. Cancer. 62:1995;403-406.
28. Clarke R.B., Howell A., Anderson E. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br. J. Cancer. 75:1997;251-257.
29. Hadsell D.L., Greenberg N.M., Fligger J.M., Baumrucker C.R., Rosen J.M. Targeted expression of des(1-3) human insulin-like growth factor I (IGF-I) in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology. 137:1996;321-330.
30. Streuli C.H., Dive C., Hickman J.A., Farrelly N., Metcalfe A. Control of apoptosis in breast epithelium. Endocrine-Related Cancer. 4:1997;45-53.
31. Peyrat J.P., Bonneterre J., Hecquet B., Vennin P., Louchez M.M., Fournier C., Lefebvre J., Demaille A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer. 29A:1993;492-497.
32. Peyrat J.P., Bonneterre J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res. Treat. 22:1992;59-67.
33. Birrel S.N., Bentel J.M., Hickey T.E., Ricciardelli C., Weger M.A., Horsfall D.J., Tilley W.D. Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 52:1995;459-467.
34. Pye J.K., Mansel R.E., Hughes L.E. Clinical experience of drug treatments for mastalgia. Lancet. 2:1985;373-377.